CIA
IMMX icon

Concurrent Investment Advisors’s Immix Biopharma IMMX Stock Holding History

Concurrent Investment Advisors’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$221K Sell
24,251
-3,180
-12% -$23.4K ﹤0.01% 1690
2025
Q4 		$143K Buy
+27,431
New +$113K ﹤0.01% 1675

Other funds holding IMMX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Concurrent Investment Advisors's IMMX Position: Q1 2026 in Review

Concurrent Investment Advisors reduced its Immix Biopharma (IMMX) stake by 12% in Q1 2026, selling an estimated $23.4K and leaving 24,251 shares worth $221K. The position accounts for ﹤0.01% of the portfolio, ranked #1690.

Concurrent Investment Advisors first reported a position in IMMX in Q4 2025 and has held it in 2 quarters since. 77 funds tracked by Wall St. Rank hold IMMX as of Q1 2026.

  • Concurrent Investment Advisors held 24,251 shares of Immix Biopharma worth $221K as of Q1 2026.
  • Concurrent Investment Advisors sold 3,180 Immix Biopharma shares in Q1 2026, an estimated $23.4K.
  • Immix Biopharma made up ﹤0.01% of Concurrent Investment Advisors's portfolio in Q1 2026, its #1690 holding.
  • Concurrent Investment Advisors first reported a position in Immix Biopharma in Q4 2025 and has held it in 2 quarters since.
  • 77 funds tracked by Wall St. Rank held Immix Biopharma as of Q1 2026.

Based on Concurrent Investment Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.